Table 1.
Patient characteristics (n = 8)
| Variable | Number |
|---|---|
| Age, years | |
| Median (range) | 69 (62–75) |
| Gender | |
| Male | 6 (75%) |
| Female | 2 (25%) |
| ECOG performance status | |
| 0 | 1 (12.5%) |
| 1 | 7 (87.5%) |
| Smoking status | |
| Former smoker | 8 (100%) |
| Never‐smoker | 0 (0%) |
| Histologic subtype | |
| Adenocarcinoma | 2 (25%) |
| Squamous cell carcinoma | 4 (50%) |
| Undifferentiated carcinoma | 2 (25%) |
| Stage | |
| III | 1 (12.5%) |
| IV | 5 (62.5%) |
| Recurrence | 2 (25%) |
| Regimen of preceding chemotherapy before nivolumab | |
| Platinum doublet | 5 (62.5%) |
| S‐1 | 2 (25%) |
| Docetaxel | 1 (12.5%) |
| Number of nivolumab administrations | |
| Median (range) | 7 (2–10) |
| Period between the last nivolumab and first salvage chemotherapy, days | |
| Median (range) | 21 (20–69) |
| Line of salvage chemotherapy | |
| Third‐line | 3 (37.5%) |
| Fourth‐line | 3 (37.5%) |
| Fifth‐line | 2 (25%) |
| Regimen of salvage chemotherapy | |
| S‐1 | 5 (62.5%) |
| Carboplatin + albumin‐bound paclitaxel | 2 (25%) |
| Docetaxel + ramucirumab | 1 (12.5%) |
ECOG, Eastern Cooperative Oncology Group.